#67
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to recognize that Cannabis Hyperemesis Syndrome (CHS) is occurring in younger patients than historically expected, requiring updated clinical awareness for emergency department triage and diagnosis. The new ICD-10 diagnosis code has improved case identification and tracking, giving providers better epidemiological data to inform patient education about dose-response relationships and risk factors. Understanding CHS incidence trends helps clinicians counsel patients on cannabis use patterns that increase hyperemesis risk, particularly as product potency and consumption methods have evolved.
A recent CDC analysis found that emergency department visits for cannabis hyperemesis syndrome (CHS) increased substantially following the introduction of a specific diagnostic code, with notably higher rates among younger patients than historically expected for a condition typically associated with chronic heavy use. This unexpected age distribution suggests either a genuine shift in CHS epidemiology among younger cannabis users, improved clinical recognition and coding practices, or both factors combined. The findings highlight that CHS, characterized by recurrent nausea, vomiting, and abdominal pain in regular cannabis users, may be more prevalent in younger demographics than previously documented in medical literature. For clinicians, these data underscore the importance of considering CHS in younger patients presenting with cyclical emesis, particularly those with regular cannabis exposure, and of accurately documenting and coding the diagnosis to better track disease trends. The improved surveillance afforded by the new diagnostic code provides clinicians with better epidemiological context for recognizing and managing this condition across diverse patient populations. Clinicians should maintain a low threshold for screening younger patients with recurrent vomiting for cannabis use patterns, as early recognition and cessation counseling remain the primary management approaches for CHS.
“We’re seeing a real uptick in cannabinoid hyperemesis syndrome diagnoses now that we have a specific billing code, which tells me we were likely undercounting cases before, but I want to be cautious about interpreting the age data until we understand whether we’re capturing true incidence shifts or simply improved detection in younger populations who may be seeking care differently than previous cohorts.”
💊 The recent increase in emergency department visits for cannabinoid hyperemesis syndrome (CHS) following the introduction of a new ICD-10 diagnosis code likely reflects improved case recognition rather than a true epidemic, though clinicians should remain alert to this diagnosis in patients presenting with cyclic vomiting and abdominal pain, particularly those with regular cannabis use. The unexpected predominance of younger patients warrants consideration of changing consumption patterns, including higher potency products and more frequent use among adolescents and young adults, which may compress the timeline to symptom development compared to historical heavy long-term users. Important confounders include increased awareness among both patients and providers following media attention, potential differences in healthcare-seeking behavior across age groups, and possible shifts in documentation practices after the code became available. Clinicians should obtain detailed cannabis use histories in patients with recurrent nausea and vomiting, counsel on dose reduction or cessation as the only defin
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
